International attention on IRLAB’s discovery platform

Biomedical Advances publishes a summary of IRLAB’s research and discovery platform, The Integrative Screening Process, ISP, with the motivation ”your paper has been selected to be featured in Biomedical Advances, because of its innovation and potential for significant impact”

ISP is a unique discovery platform designed for efficient discovery of novel treatment strategies for neurological and neuropsychiatric disorders. The paper featured by Biomedical Advances describes the application of IRLAB’s in vivo systems response profiling for CNS drug discovery through the process referred to as the Integrative Screening Process, ISP. Biomedical Advances now publishes a supplement and a link to the article at http://biomedical-advances.org/neuro-20179-12/.

The ISP technology emanates from an integrative view on disease and drug effects. Based on a systems level perspective, the evaluation of new chemical entities is focused primarily on comprehensive, phenotypic characterization. IRLAB has built a large proprietary database on drug response profiles and by means of advanced data mining and machine learning techniques, link the response profiles both to chemical properties of the molecules, and to clinical effects as observed in human.

The application of a structured methodology for such phenotypic characterization is described in the paper published in 2017 by American Chemical Society (ACS) Chemical Neurosciences. The paper is one of ACSs most read research articles during the past twelve months. We argue that the approach presented provides not only a major step towards more efficient CNS drug discovery, but also a means for gaining better understanding of CNS drug actions as such. The original article can be found at www.bit.ly/IRLAB_ACS.

“The feature of ISP by Biomedical Advances highlights that IRLAB is at the forefront of contemporary science. The brain, and disorders of the brain are complex and innovative approaches are needed to discover and develop treatments. By means of ISP we can continue our work to discover new, effective and safe, treatment strategies for these complex disorders” says Nicholas Waters, CEO.

“Both IRL752 and IRL790, IRLAB’s two development compounds in Phase II studies were discovered by ISP. Over the last few years, IRLAB has filed two new patent applications on compounds developed using ISP, and we expect to nominate an additional development compound within our P001 research programme shortly. This illustrates the efficiency of ISP and our organization”, says Clas Sonesson, CSO.

For further information

Nicholas Waters, CEO 
Phone: +46 730 75 77 01                
E-mail: nicholas.waters@irlab.se

Clas Sonesson, CSO 
Phone: +46 730 75 77 00
E-mail: clas.sonesson@irlab.se

About IRLAB

IRLAB is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.

IRLAB has two clinical candidate drugs, IRL752 and IRL790, focused on medical needs in Parkinson’s disease. IRLAB also has additional programs in pre-clinical stages.

IRLAB’s research is aimed at discovery and development of new candidate drugs addressing unmet medical need in diseases of the central nervous system, using the unique and proprietary integrative screening process, ISP.

IRLAB is based in Gothenburg, Sweden. The operations are mainly carried out through the subsidiary Integrative Research Laboratories Sweden AB.

For more information, please visit www.irlab.se.

Subscribe

Quotes

The feature of ISP by Biomedical Advances highlights that IRLAB is at the forefront of contemporary science. The brain, and disorders of the brain are complex and innovative approaches are needed to discover and develop treatments. By means of ISP we can continue our work to discover new, effective and safe, treatment strategies for these complex disorders.
Nicholas Waters, CEO
Both IRL752 and IRL790, IRLAB’s two development compounds in Phase II studies were discovered by ISP. Over the last few years, IRLAB has filed two new patent applications on compounds developed using ISP, and we expect to nominate an additional development compound within our P001 research programme shortly. This illustrates the efficiency of ISP and our organization.
Clas Sonesson, CMO